Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRODIGE 50 - ASPIK: Aspirin versus placebo in resected colon cancer with PI3K mutation
2024-516007-16-00Phase 3Authorised
- Sponsor
- Rouen University Hospital
- Start
- Sep 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in colon adenocarcinoma comparing Aspirin Protect arm with Placebo arm (2 arms). Primary endpoint: Disease-free survival at 3 years. Planned start Sep 2024; status: authorised.
02
Drugs
Cartia
03
Conditions
colon adenocarcinoma
Beyond the preview
Go deeper on 2024-516007-16-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-516007-16-00.